Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan

Chun-Chou Tsai a, Yung-Chih Wang a, Tsung-Ta Chiang a, I.-An Chen b, Chun-Hsiang Chiu a,* Ya-Sung Yang a, Kuo-Ming Yeh a, Feng-Yee Chang a

a Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
b National Defense Medical Center, Taipei, Taiwan

Received 18 May 2020; received in revised form 15 July 2020; accepted 23 July 2020

KEYWORDS
COVID-19; Taiwan; Clinical characteristics

Background: Coronavirus disease-2019 (COVID-19) is a worldwide pandemic. We present the clinical characteristics and outcomes of 28 COVID-19 patients treated in our hospital in Taiwan. Methods: Patients with COVID-19, confirmed by positive real-time reverse-transcriptase polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral nucleic acids from oropharyngeal swab specimens between February 4, 2020 and July 6, 2020, were enrolled. Their clinical characteristics and outcomes were reviewed. Results: Seventeen of the 28 patients (60.7%) had pneumonia. The most frequent symptoms were cough (n = 23, 82.1%) and fever (n = 17, 60.7%). The development of pneumonia was associated with age ≥ 40 years (p = 0.024), body mass index (BMI) ≥ 25 kg/m² (p = 0.014), fever (p = 0.007), shortness of breath (p = 0.036), chills (p = 0.047), and lower platelet counts (< 200,000/μL) (p = 0.007). Increased quarantine duration was associated with age ≥ 40 years (p = 0.026), Charlson index ≥ 1 (p = 0.037), lower lymphocyte (< 1500/μL; p = 0.028) or platelet counts (< 200,000/μL) (p = 0.016), lower serum sodium (< 140 mEq/L; p = 0.006), and higher C-reactive protein (CRP) level (≥ 1 mg/dl; p = 0.04). Treatment with hydroxychloroquine or in combination with other medicines did not reduce the quarantine duration. All 28 patients recovered with a median quarantine duration of 27.2 days. Conclusion: COVID-19 patients with older age, higher BMI, fever, chills or shortness of breath, lower serum sodium level, lower platelet or lymphocyte count, and higher CRP level may be associated with developing pneumonia or longer quarantine duration.

* Corresponding author. Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, 7F, No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan. Fax: +886 2 87927258.
E-mail address: pipi10279@gmail.com (C.-H. Chiu).

https://doi.org/10.1016/j.jfma.2020.07.033
0929-6646/© 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The coronavirus disease-2019 (COVID-19) outbreak is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak was initially identified in Wuhan, China in December 2019 and has been a public health emergency of international concern since its spread within China and worldwide.1–4 Many COVID-19 patients are reportedly asymptomatic or mildly ill with only flu-like symptoms such as fever and cough. However, many patients develop pneumonia, acute respiratory distress syndrome, and multiple organ failure in a short time.5–7 Identifying the risk factors for developing pneumonia, longer quarantine duration, and mortality in COVID-19 patients is important. However, due to the Taiwan government’s rapid action on the disease, including border control, compulsory quarantine, and comprehensive contact tracing, Taiwan has been able to contain the pandemic. Thus, there are limited data regarding the clinical characteristics of COVID-19 patients in Taiwan.

Our hospital, the Tri-Service General Hospital, is a tertiary medical center in Northern Taiwan with 12 airborne infection isolation rooms and eight airborne infection isolation critical care rooms. Since February 4, 2020, 28 confirmed COVID-19 patients were admitted to our airborne infection isolation rooms. All patients were discharged with recovery. Due to the limited available data on the clinical characteristics of COVID-19 patients in Taiwan, we conducted this study to clarify the risk factors for developing pneumonia and longer quarantine duration in COVID-19 patients in Taiwan.

Methods

Study population

Adult patients (age ≥20 years) with COVID-19 infection, as confirmed by positive identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral nucleic acids, were enrolled. These were confirmed using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assays from oropharyngeal swab specimens collected between February 4, 2020, and July 6, 2020. Positive patients were admitted to our airborne infection isolation wards at Tri-Service General Hospital and included in our study. The study was approved by the Institutional Review Board of Tri Service General Hospital and informed consent was obtained from the included patients.

Demographic, clinical symptom, laboratory, and medication data

Relevant clinical data on the enrolled patients, including age, sex, height, weight, imported or indigenous transmission, underlying diseases, clinical symptoms, laboratory data, treatment medicine, and hospitalization days, were recorded. Pneumonia was diagnosed as the presence of lower respiratory tract symptoms such as cough, systemic symptoms such as fever, and new onset radiology findings of infiltration.8,9

Data on the clinical symptoms were collected from patient accounts at and during admission. Laboratory data including white cell counts, platelet counts, neutrophil and lymphocyte ratios; total bilirubin, albumin, creatine kinase C-reactive protein (CRP), D-dimer, procalcitonin, myoglobin, ferritin, lactic dehydrogenase, and alkaline phosphatase levels; and erythrocyte sedimentation rates were examined in patients 24 h after admission. Renal function was assessed based on blood urea nitrogen and creatinine measurements, while liver function was assessed according to aspartate transaminase and alanine transaminase concentrations. The cycle threshold (Ct) values of the COVID-19 RT-PCR assays from the oropharyngeal swab specimens were also obtained. Patients who were discharged fulfilled the criteria decided by Taiwan’s Centers for Disease Control, which required the symptoms to have subsided as well as three negative COVID-19 test results from oropharyngeal swab specimens and sputum.

Statistical analysis

The patients were sub-grouped according to demographic data, symptoms, laboratory data, and treatment medicines to clarify the risk factors for developing pneumonia and long quarantine duration. All results were analyzed using a commercially available software package (IBM SPSS Statistics for Windows, version 21.0; IBM Corp., Armonk, NY, USA). Categorical variables were analyzed using chi-squared tests. Continuous variables with categorical variables were analyzed using independent sample t-tests. The odds ratio of each factor were obtained by logistic regression tests. All p-values were two-tailed, and values less than 0.05 were considered statistically significant.

Results

Our study included a total of 28 COVID-19 confirmed patients hospitalized and discharged between February 4, 2020, and July 6, 2020 at Tri Service General Hospital. The median age of these patients was 41 years (range, 18–80 years). Among them, 17 patients (60.7%) had pneumonia. All 28 patients recovered and were discharged, with a median hospital quarantine duration was 27.2 days. The median Charlson comorbidity index of these patients was 0.93.
Successful treatment of coronavirus disease

Associations between demographic data and outcomes

The sub-grouped demographic data are shown in Table 1. The incidence between men and women was equal (50% men vs. 50% women). Most of the patients (n = 25; 89.3%) had a travel history and were classified as imported cases. Four patients (14.3%) had underlying hypertension and five (17.9%) had underlying hyperlipidemia. More patients who were 40 years old or older developed pneumonia compared to patients younger than 40 (84.6% vs. 40%; p = 0.024). More patients who developed pneumonia had a BMI greater than or equal to 25 compared to those with a BMI under 25 kg/m² (100% vs. 47.6%; p = 0.014). More patients shorter than 1.7 m developed pneumonia compared to patients taller than 1.7 m (25% vs. 75%; p = 0.023). Patients 40 years of age or older had a longer quarantine duration compared to that in patients younger than 40 years (31.7 ± 10.8 days vs. 23.3 ± 8.1 days; p = 0.026). Patients with a higher Charlson comorbidity index had a longer quarantine duration than that in patients with a lower Charlson comorbidity index (32.2 ± 11.6 days vs. 24.8 ± 8.1 days; p = 0.037).

Associations between laboratory findings and outcomes

The laboratory results of these COVID-19 patients, confirmed within 24 h after admission, are listed in Table 3. Among these confirmed cases, 16 patients (57.1%) had a relatively lower absolute lymphocyte count (ALC) (<1500/ul). They were more prone to a longer quarantine duration than that in patients with a higher ALC (21.9 ± 9 days vs. 31.2 ± 9.5 days; p = 0.028). Eight patients (28.6%) had a relatively lower platelet count (<200,000/ul). They were more prone to having pneumonia (45% vs. 100%; p = 0.007) and a longer quarantine duration (24.4 ± 8.6 days vs. 34.3 ± 11 days; p = 0.016) than those in patients with a higher platelet count. Patients with relatively low serum sodium (<140 mmol/L) (71.4%) levels or higher CRP levels (≥1 mg/dl) were prone to longer quarantine durations than patients with higher serum albumin or lower CRP levels (Na ≥140 mmol/L vs. Na < 140 mmol/L; 19.1 ± 5.6 days vs. 30.5 ± 10 days; p = 0.006) (CRP ≥1 mg/dl vs. CRP <1 mg/dl; 32.5 ± 11.8 days vs 24.3 ± 8.2 days; p = 0.04).

Discussion

The COVID-19 outbreak first occurred in Wuhan, China in December 2019 and has spread worldwide in just 2 months. Since February 21, 451 confirmed COVID-19 cases have been

| Table 1 | Demographic data of patients with coronavirus disease-2019 (COVID-19). |
|----------|---------------------------------------------------------------|
|          | Number (%) | No pneumonia | Pneumonia | Odds ratio | p value | Quarantine duration (days) | p value |
| Sex      |            |              |           |            |         |                           |         |
| Male     | 14 (50%)   | 7 (50%)      | 7 (50%)   | 0.4 (0.084–1.909) | 0.25 | 28.9 ± 7.7                 | 0.387 |
| Female   | 14 (50%)   | 4 (28.6%)    | 10 (71.4%)| 1           | 0.024 | 23.3 ± 8.1                 | 0.026 |
| Age (years) |          |              |           |            |         |                           |         |
| ≥40      | 13 (46.4%) | 2 (15.4%)    | 11 (84.6%)| 8.25 (1.328–51.263) | 0.014 | 34.0 ± 11.7                | 0.051 |
| <40      | 15 (53.6%) | 9 (60%)      | 6 (40%)   | 1           | 0.25  | 25.5 ± 12.4                | 0.387 |
| BMI (kg/m²) |      |              |           |            |         |                           |         |
| ≥25      | 7 (25%)    | 0            | 7 (100%)  | NA          | 0.004 | 23.3 ± 8.1                 | 0.016 |
| <25      | 21 (75%)   | 11 (52.4%)   | 10 (47.6%)| NA          | 0.014 | 34.0 ± 11.7                | 0.051 |
| Height (m) |          |              |           |            |         |                           |         |
| ≥1.7     | 8 (28.6%)  | 6 (75%)      | 2 (25%)   | 0.111 (0.017–0.738) | 0.023 | 32.2 ± 11.6                | 0.544 |
| <1.7     | 20 (71.4%) | 5 (20%)      | 15 (75%)  | 1           | 0.023 | 26.5 ± 11.1                | 0.037 |
| Source   |            |              |           |            |         |                           |         |
| Imported | 25 (89.3%) | 9 (36%)      | 16 (64%)  | 3.6 (0.282–44.884) | 0.032 | 27.2 ± 10.6                | 0.937 |
| Indigenous | 3 (10.7%) | 2 (66.7%)    | 1 (33.3%) | 1           | 0.078 | 24 ± 8.1                   | 0.037 |
| Charlson Index | |          |           |            |         |                           |         |
| ≥1       | 11 (39.3%) | 2 (18.1%)    | 9 (81.8%) | 5.1 (0.833–30.75) | 0.023 | 26.5 ± 11.1                | 0.037 |
| <1       | 17 (60.7%) | 9 (52.9%)    | 8 (47.1%) | 1           | 0.023 | 24 ± 8.1                   | 0.037 |
reported in Taiwan. Due to the Taiwan government’s rapid actions, the country has been able to contain the pandemic. Thus, there are limited data on the clinical characteristics of COVID-19 patients in Taiwan. Since February 2020, 28 confirmed COVID-19 patients had been admitted to our hospital. All patients recovered and were discharged. Our study aimed to present the clinical characteristics of COVID-19 patients in Taiwan and to clarify the risk factors for developing pneumonia and longer quarantine durations.

Confirmed COVID-19 patients in Taiwan can leave quarantine only after three negative COVID-19 tests. Due to the long communicability period of COVID-19 and the relatively mild disease severity of confirmed patients in our hospital, all of our COVID-19 patients recovered from the disease before they obtained three negative COVID-19 test results required to leave quarantine. Thus, the quarantine duration in the present study more reflected the time required for virus eradication rather than disease severity.

All patients with confirmed COVID-19 in our hospital recovered eventually. Several factors may have contributed to the lack of mortality. First, our COVID-19 patients were relatively young with well performance. Most were classified as imported cases (n = 25; 89.3%) and had gone abroad for study or tourism. As in a previous study, patients with comorbidity showed poorer clinical outcomes than those without. Second, most of our COVID-19 patients had relatively mild illnesses. Among them, only one patient developed acute respiratory distress syndrome (ARDS) (n = 1; 3.6%) while other studies reported much higher percentages of patient developing ARDS. Third, most of our patients were diagnosed in the early stage of disease. Symptomatic patients who visited our hospital with a travel or contact history were all referred to our emergency room and tested for COVID-19. Timely identification of patients at risk allowed early diagnosis and relatively mild disease severity in our patients. Finally, successful supportive treatment may also play a role. Optimized supportive care remains the mainstay of therapy for COVID-19, and the clinical efficacy for the subsequent agents is still under investigation.

In our study, older COVID-19 patients (age ≥40 years) were prone to having pneumonia and a longer quarantine period compared to younger patients (Table 1). Older age is reportedly associated with higher mortality in COVID-19 patients. This may be due to the age-dependent differences in activity and expression of pulmonary renin-angiotensin system components under pathophysiologic conditions. An animal study reported increased fluid-soluble angiotensin-converting enzyme activity was in bronchoalveolar lavage of rats exposed to lipopolysaccharide. This increased enzyme activity was significantly higher

| Symptoms of patients with coronavirus disease-2019 (COVID-19). |
|---------------------------------------------------------------|
| Number (%) | No pneumonia | Pneumonia | Odds ratio | p value | Quarantine duration (days) | p value |
|------------|---------------|-----------|------------|---------|--------------------------|---------|
| Fever      | Yes 17 (60.7%) | 3 (17.6%) | 14 (82.4%) | 12.444 (2.015–76.872) | 29.7 ± 9.4 | 0.007 |
|            | No 11 (39.3%) | 8 (72.7%) | 3 (27.3%)  | 1        | 23.4 ± 10.7              | 0.198   |
| Cough      | Yes 23 (82.1%) | 9 (39.1%) | 14 (60.9%) | 1.037 (0.144–7.477)   | 27.3 ± 10.2 | 0.971   |
|            | No 5 (17.9%)  | 2 (40%)   | 3 (60%)    | 1        | 27 ± 11.9                | 0.96    |
| Headache   | Yes 4 (14.3%)  | 0         | 4 (100%)   | NA       | 22.7 ± 3.7               | 0.082   |
|            | No 24 (85.7%) | 11 (45.8%)| 13 (54.2%) | NA       | 27.9 ± 10.8              | 0.357   |
| Myalgia    | Yes 5 (17.9%)  | 1 (20%)   | 4 (80%)    | 3.077 (0.296–31.982)  | 32 ± 9.5 | 0.347 |
|            | No 23 (82.1%) | 10 (43.5%)| 13 (56.5%) | 1        | 26.2 ± 10.3              | 0.258   |
| Distorted sense of taste | Yes 7 (25%) | 3 (42.9%) | 4 (57.1%) | 0.821 (0.144–4.66) | 29.6 ± 8.3 | 0.842 |
|            | No 21 (75%)  | 8 (38.1%) | 13 (61.9%) | 1        | 26.4 ± 10.9              | 0.493   |
| Distorted sense of smell | Yes 10 (35.7%) | 5 (50%)   | 5 (50%)    | 0.5 (0.103–2.428)    | 25.7 ± 10.1 | 0.39    |
|            | No 18 (64.3%) | 6 (33.3%) | 12 (66.7%) | 1        | 28.1 ± 10.5              | 0.571   |
| Rhinorrhea | Yes 12 (42.9%) | 4 (33.3%) | 8 (66.7%)  | 1.556 (0.329–7.361)  | 26.8 ± 10 | 0.577   |
|            | No 16 (57.1%) | 7 (43.8%) | 9 (56.2%)  | 1        | 27.6 ± 10.7              | 0.84    |
| Sore throat| Yes 8 (28.6%)  | 1 (12.5%) | 7 (87.5%)  | 7 (0.722–67.84)      | 28.6 ± 9.9 | 0.971   |
|            | No 20 (71.4%) | 10 (50%)  | 10 (50%)   | 1        | 26.7 ± 10.6              | 0.654   |
| Diarrhea   | Yes 10 (35.7%) | 2 (20%)   | 8 (80%)    | 4 (0.659–24.297)    | 25.3 ± 11.4 | 0.132   |
|            | No 18 (64.3%) | 9 (50%)   | 9 (50%)    | 1        | 28.3 ± 9.8               | 0.473   |
| Chest pain | Yes 5 (17.9%)  | 1 (20%)   | 4 (80%)    | 3.077 (0.296–31.982) | 21.6 ± 4.2 | 0.347   |
|            | No 23 (82.1%) | 10 (43.5%)| 13 (56.5%) | 1        | 28.4 ± 10.8              | 0.182   |
| Shortness of breath | Yes 10 (35.7%) | 1 (10%)   | 9 (90%)    | 11.25 (1.167–108.407) | 30.1 ± 11.8 | 0.036   |
|            | No 18 (64.3%) | 10 (55.6%)| 8 (44.4%)  | 1        | 25.6 ± 9.3               | 0.276   |
| Chillness  | Yes 5 (17.9%)  | 0         | 5 (100%)   | NA       | 20.8 ± 4                 | 0.125   |
|            | No 23 (82.1%) | 11 (47.8%)| 12 (52.2%) | NA       | 19 ± 2.6                | 0.14    |
| Nausea/vomiting | Yes 3 (10.7%) | 0         | 5 (100%)   | NA       | 28.2 ± 10.4              | 0.146   |
|            | No 25 (89.3%) | 11 (44%)  | 14 (56%)   | 1        | 23                         |         |
| Eye illness| Yes 1 (3.6%)   | 0         | 1 (100%)   | NA       | 27.4 ± 10.4              | 0.684   |

Table 2
Table 3  Laboratory findings of patients with coronavirus disease-2019 (COVID-19) during admission.

| White blood cell count (/μL) | ≥4000 | 23 (82.1%) | 10 (43.5%) | 13 (56.5%) | 1 | 27.7 ± 10.7 |
| CK (u/L) | ≥50 | 11 (44%) | 4 (36.4%) | 7 (63.6%) | 1 | 27.9 ± 6.5 |
| C reactive protein (mg/dL) | ≥1 | 6 (21.4%) | 1 (16.6%) | 5 (83.3%) | 4.167 (0.416-417.76) | 0.225 | 27.1 ± 6.4 |
| AST (u/L) | ≥20 | 13 (46.4%) | 6 (46.2%) | 7 (53.8%) | 1 | 26.3 ± 12.4 |
| ALT (u/L) | ≥20 | 11 (39.3%) | 4 (36.3%) | 7 (63.6%) | 1 | 25.7 ± 13.1 |
| Total bilirubin (mg/dL) | ≥0.5 | 18 (66.7%) | 8 (44.4%) | 10 (55.6%) | 1 | 28.5 ± 11.3 |
| Albumin (g/dL) | ≥4 | 14 (53.8%) | 4 (26.8%) | 10 (71.4%) | 1 | 26.7 ± 9.0 |
| Na (mmol/L) | ≥140 | 8 (28.6%) | 4 (50%) | 4 (50%) | 1 | 19.1 ± 5.6 |
| K (mmol/L) | ≥3.5 | 23 (82.1%) | 10 (43.5%) | 13 (56.5%) | 1 | 27.0 ± 8.0 |
| C-reactive protein (mg/dL) | ≥1 | 10 (35.7%) | 2 (20%) | 8 (80%) | 1 | 32.5 ± 11.8 |
| D-dimer (μg/mL) | ≥0.5 | 3 (27.3%) | 1 (33.3%) | 2 (66.7%) | 1 | 32 ± 7 |
| Procalcitonin (ng/mL) | ≥0.03 | 7 (70%) | 1 (14.2%) | 6 (85.7%) | NA | 31.2 ± 12.2 |
| Myoglobin (ng/mL) | ≥10 | 8 (66.7%) | 3 (37.5%) | 5 (62.5%) | 1 | 25.7 ± 7.8 |
| Ferritin (ng/mL) | ≥200 | 9 (56.2%) | 2 (18.2%) | 7 (81.8%) | 1 | 28.2 ± 10.6 |
| Lactate dehydrogenase (u/L) | ≥150 | 15 (57.7%) | 5 (33.3%) | 10 (66.7%) | 1 | 26.5 ± 11.4 |
| Alkaline-phosphatase (u/L) | ≥50 | 15 (62.5%) | 6 (40%) | 9 (60%) | 1 | 31.2 ± 9.6 |
| Erythrocyte sedimentation rate (mm/hr) | ≥20 | 6 (75%) | 1 (16.6%) | 5 (83.3%) | NA | 24.6 ± 6.9 |
| Cycle threshold of RT-PCR | ≥25 | 16 (59.3%) | 6 (37.5%) | 10 (62.5%) | 1 | 29.0 ± 8.7 |

in elderly rats. This may indicate that the elderly are more prone to the development and progression of lung injuries. COVID-19 patients who were overweight (BMI ≥25 kg/m²) were more likely to have pneumonia than those who were non-overweight patients (Table 1). This risk factor was also reported in H1N1-infected patients. In previous studies, obesity was found to increase H1N1 vulnerability and may be associated with the need for hospitalization and death in H1N1 patients. Patients with a high Charlson comorbidity index (≥1) in our study had longer quarantine durations (Table 1). A previous study suggested that the Charlson comorbidity index might serve as an independent determinant for hospital mortality in COVID-19 patients. Our study revealed that it might also serve as a determinant for hospital quarantine durations in COVID-19 patients. The most frequent symptoms in our patients were cough and fever (Table 2). This finding was similar to those of other studies. A growing number of papers have reported smell or taste disturbances in COVID-19 patients. In our study, 10 (35.7%) and seven patients (25%) had distorted
senses of smell and taste, respectively (Table 2). Changes in smell and taste in COVID-19 patients may be related to angiotensin-converting enzyme 2 protein in nasal respiratory and olfactory epithelial cells. Most of the patients in our hospital with distorted smell or taste gradually recovered their senses following their recovery. Based on these symptoms, a team at King’s College London developed a model to identify which combination of symptoms could predict COVID-19 cases, including a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhea, abdominal pain, and loss of appetite. They found that the strongest predictor was loss of smell and taste. Clinical physicians should be on alert in patients with symptoms of distorted smell or taste.

A previous study reported that lymphopenia might be associated with severe COVID-19. The results of our study showed that it may also be associated with longer hospital quarantine (Table 3). A meta-analysis of nine studies suggested that thrombocytopenia was significantly associated with COVID-19 severity. A more sizable drop in platelet counts was noted, especially in non-survivors. In our study, a lower platelet count (<200,000/μL) might also be associated with developing pneumonia and longer hospital quarantine duration (Table 3). Lower serum sodium levels may indicate poor nutrition and health status. In our study, serum sodium (<140 mmol/L) was associated with longer hospital quarantine (Table 3). A previous study reported a high prevalence of malnutrition in elderly COVID-19 patients. Low real-time RT-PCR cycle threshold (Ct) values of COVID-19 from oropharyngeal swabs indicated high viral loads. However, in our study, there was no relationship between Ct values and the occurrence of pneumonia or longer hospital quarantine. We could not predict the outcome or disease severity using the virus Ct. Yen et al. reported similar viral loads between asymptomatic and symptomatic patients. Additional studies are needed to clarify the correlation between viral loads and disease severity or COVID-19 patient outcomes.

Hydroxychloroquine and azithromycin reportedly decrease viral load in COVID-19 patients. We prescribed hydroxychloroquine to most of the enrolled patients; however, the hospital quarantine duration did not differ significantly between patients who received hydroxychloroquine and those who did not (Table 4). This may be due to the small number of cases in our study. Further studies on the efficacy of hydroxychloroquine or azithromycin are needed. However, a previous study reported that hydroxychloroquine may not reduce the need for intubation or mortality in COVID-19 patients. The combination of hydroxychloroquine and different antibiotics in our study did not reduce the duration of hospital quarantine (Table 4). Further studies are needed to clarify the efficacy of these agents.

Our study has several limitations. First, it was conducted in a single center; thus, the results may have some biases. Second, this was a retrospective cohort study and not all laboratory examinations were performed in all patients. Third, our treatment options were not chosen randomly, which may also have caused biases. Fourth, due to the small sample size of our study, multivariate logistic regression analysis was difficult to perform to assess the relationship between the outcome (developing pneumonia and increased quarantine duration) and the predictive factors. Further studies are needed to clarify the clinical characteristics and efficacy of treatment options in COVID-19 patients.

### Table 4: Treatment medications and durations of coronavirus disease-2019 (COVID-19) patient quarantine.

| Medication Combinations                              | Number (%) | Quarantine duration (days) | p value |
|------------------------------------------------------|------------|----------------------------|---------|
| Hydroxychloroquine + Azithromycin + Ceftriaxone + Teicoplanin | Yes: 3 (10.7%) | 28.6 ± 2.8 | 0.801 |
|                                                      | No: 25 (89.3%) | 27.0 ± 10.8 |         |
| Hydroxychloroquine + Azithromycin + Ceftriaxone     | Yes: 10 (35.7%) | 27.4 ± 9.3 | 0.877 |
|                                                      | No: 18 (64.3%) | 26.8 ± 12.3 |         |
| Hydroxychloroquine + Azithromycin                   | Yes: 13 (46.4%) | 28.4 ± 11.3 | 0.56   |
|                                                      | No: 15 (53.6%) | 26.1 ± 9.5  |         |
| Hydroxychloroquine + Ceftriaxone                    | Yes: 13 (46.4%) | 25.3 ± 11.1 | 0.39   |
|                                                      | No: 15 (53.6%) | 28.8 ± 9.6  |         |
| Hydroxychloroquine                                   | Yes: 22 (78.6%) | 26.3 ± 10.7 | 0.363  |
|                                                      | No: 6 (21.4%)  | 30.6 ± 8.4   |         |
| Ceftriaxone                                           | Yes: 16 (57.1%) | 27.6 ± 11.2 | 0.812  |
|                                                      | No: 12 (42.9%) | 26.7 ± 9.3   |         |
| Azithromycin                                          | Yes: 13 (46.4%) | 28.4 ± 11.3 | 0.56   |
|                                                      | No: 15 (53.6%) | 26.1 ± 9.5   |         |
| No Antibiotics or Hydroxychloroquine                 | Yes: 3 (10.7%) | 24 ± 3.6     | 0.576  |
|                                                      | No: 25 (89.3%) | 27.6 ± 10.8  |         |
Funding
This work was supported by Tri-Service General Hospital, Taipei, Taiwan [grant numbers TSGH-C108-135 and TSGH-C109-147]; and the National Science Council, Taipei, Taiwan [grant numbers MOST 106-2314-B016-024-MY3].

Declaration of Competing Interest
The authors have no conflicts of interest relevant to this article.

References

1. World Health Organization. Pneumonia of unknown cause—China. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/; 2020.
2. World Health Organization. Novel coronavirus—China. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/; 2020.
3. Zhu N, Zhang D, Wang W, Xingwang L, Bo Y, Jingdong S, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382: 72-33.
4. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it; 2020.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2002321.
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395: 507–13.
7. Yang X, Yu Y, Xu J, Shi H, Xia J, Lü H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475–81.
8. Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med 2014;370(6):543–51.
9. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoeppelman AI, Kluytman JA, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312–23.
10. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, etc. Comorbidity and its impact on 1590 patients with COVID-19 in China: a Nationwide Analysis. Eur Respir J 2020;55(5).
11. Tang X, Du R, Wang R, Cao T, Guan L, Yang C, etc. Comparison of hospitalized patients with acute respiratory distress syndrome caused by covid-19 and H1N1. Chest 2020;158(1): 195–205.
12. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, etc. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med 2020;180(7):934–43.
13. Zhou Fei, Ting Yu, Du Ronghui, Fan Guohui, Liu Ying, Liu Zhibo, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
14. Schouten LR, Helmerhorst HJ, Wagenaar GT, Haltenhof T, Lutter R, Roelofs JJ, et al. Age-dependent changes in the pulmonary renin-angiotensin system are associated with severity of lung injury in a model of acute lung injury in rats. Crit Care Med 2016;44(12):e1226–35.
15. Misumi I, Starmer J, Uchimura T, Beck MA, Magnuson T, Whitmire JK. Obesity expands a distinct population of T cells in adipose tissue and increases vulnerability to infection. Cell Rep 2019;27:514–524 e5.
16. Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S, et al. Obesity increases the duration of influenza A virus shedding in adults. J Infect Dis 2018;218:1378–82.
17. Yali Q, Zhuo L, Ziqiang D, Yanfang Z, Hongjun M. Prognostic value of Charliton's weighted index of Capabilities combined with Chronic health evaluation II score in COVID-19: a retrospective cohort study. BMC Infect Dis 2020. https://doi.org/10.1186/s12879-020-05956-x.
18. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study. J Otolaryngol Head Neck Surg 2020;49:26.
19. Brann DTT, Weinreb C, Logan D, Datta S. Non-neural expression of SARS-CoV2 entry genes in the olfactory epithelium suggests mechanisms of underlying anosmia in COVID-19. Biorxiv.org 2020. https://doi.org/10.1101/2020.03.25.009084.
20. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic—an observational cohort study. J Otolaryngol Head Neck Surg 2020;49(1):1–6.
21. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis 2020. https://doi.org/10.1016/j.ijid.2020.04.086.
22. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020 13;506: 145–8.
23. Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr 2020. https://doi.org/10.1038/s41430-020-0642-3.
24. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;12:1177–9.
25. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized trial. Int J Antimicrob Agents 2020:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
26. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hricak G, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2012410.